10.00

2.10% -0.215

After Hours: 10.00

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $10.00, with a volume of 1.04M. It is down -2.10% in the last 24 hours and up +10.86% over the past month. Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Previous Close:

$10.21

Open:

$10.22

24h Volume:

1.04M

Relative Volume:

0.33

Market Cap:

$1.61B

Revenue:

$68.56M

Net Income/Loss:

$-437.99M

P/E Ratio:

-3.1607

EPS:

-3.1639

Net Cash Flow:

$-396.61M

1W Performance:

-3.57%

1M Performance:

+10.86%

6M Performance:

+67.79%

1Y Performance:

+64.47%

1-Day Range:

$9.94

$10.43

1-Week Range:

$9.94

$10.90

52-Week Range:

$4.155

$11.66

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

367

Twitter

@Vir_Biotech

Next Earnings Date

2026-05-06

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	10.00	1.65B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	423.92	108.71B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	74.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.61B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	41.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.81B	5.36B	287.73M	924.18M	2.5229

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Upgrade	Raymond James	Outperform → Strong Buy
Sep-03-25	Initiated	Evercore ISI	Outperform
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

Apr 30, 2026

Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust - Stock Titan

Apr 30, 2026

Vir Biotechnology prices $150M stock offering - MSN

Apr 30, 2026

Apr 29, 2026

[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 29, 2026

Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration - Yahoo Finance

Apr 29, 2026

Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 28, 2026

Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Apr 28, 2026

Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 28, 2026

Apr 27, 2026

Brii Bio reports durable HCB control in Phase II analysis - The Pharma Letter

Apr 27, 2026

Apr 26, 2026

Vir Biotechnology launches $200M public stock offering - MSN

Apr 26, 2026

Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Is VIR a Good Stock to Buy? - HarianBasis.co

Apr 26, 2026

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey

Apr 26, 2026

Apr 24, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace

Apr 24, 2026

Apr 23, 2026

Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛

Apr 23, 2026

Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union

Apr 23, 2026

Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks

Apr 23, 2026

Apr 22, 2026

Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co

Apr 22, 2026

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey

Apr 22, 2026

Apr 21, 2026

VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 21, 2026

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st

Apr 21, 2026

Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co

Apr 21, 2026

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia

Apr 20, 2026

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat

Apr 20, 2026

Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com

Apr 20, 2026

Apr 19, 2026

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey

Apr 19, 2026

Apr 18, 2026

8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey

Apr 18, 2026

Apr 17, 2026